358 related articles for article (PubMed ID: 2043664)
1. Mechanism of action of the antiplatelet peptide, arietin, from Bitis arietans venom.
Huang TF; Wang WJ; Teng CM; Ouyang C
Biochim Biophys Acta; 1991 May; 1074(1):144-50. PubMed ID: 2043664
[TBL] [Abstract][Full Text] [Related]
2. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
Huang TF; Liu CZ; Ouyang CH; Teng CM
Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
[TBL] [Abstract][Full Text] [Related]
3. Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein IIb-IIIa complex.
Huang TF; Sheu JR; Teng CM; Chen SW; Liu CS
J Biochem; 1991 Feb; 109(2):328-34. PubMed ID: 1864844
[TBL] [Abstract][Full Text] [Related]
4. Purification and characterization of an antiplatelet peptide, arietin, from Bitis arietans venom.
Huang TF; Wang WJ; Teng CM; Liu CS; Ouyang C
Biochim Biophys Acta; 1991 May; 1074(1):136-43. PubMed ID: 2043663
[TBL] [Abstract][Full Text] [Related]
5. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex.
Huang TF; Holt JC; Lukasiewicz H; Niewiarowski S
J Biol Chem; 1987 Nov; 262(33):16157-63. PubMed ID: 3680247
[TBL] [Abstract][Full Text] [Related]
6. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
Rahman S; Lu X; Kakkar VV; Authi KS
Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
[TBL] [Abstract][Full Text] [Related]
7. Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function.
Savage B; Marzec UM; Chao BH; Harker LA; Maraganore JM; Ruggeri ZM
J Biol Chem; 1990 Jul; 265(20):11766-72. PubMed ID: 2365698
[TBL] [Abstract][Full Text] [Related]
8. A new short chain RGD-containing disintegrin, accutin, inhibits the common pathway of human platelet aggregation.
Yeh CH; Peng HC; Yih JB; Huang TF
Biochim Biophys Acta; 1998 Nov; 1425(3):493-504. PubMed ID: 9838213
[TBL] [Abstract][Full Text] [Related]
9. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG
Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080
[TBL] [Abstract][Full Text] [Related]
10. An antiplatelet peptide, gabonin, from Bitis gabonica snake venom.
Huang TF; Peng HC; Peng IS; Teng CM; Ouyang C
Arch Biochem Biophys; 1992 Oct; 298(1):13-20. PubMed ID: 1524422
[TBL] [Abstract][Full Text] [Related]
11. Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets.
Huang TF; Holt JC; Kirby EP; Niewiarowski S
Biochemistry; 1989 Jan; 28(2):661-6. PubMed ID: 2653425
[TBL] [Abstract][Full Text] [Related]
12. A potent antiplatelet peptide, triflavin, from Trimeresurus flavoviridis snake venom.
Huang TF; Sheu JR; Teng CM
Biochem J; 1991 Jul; 277 ( Pt 2)(Pt 2):351-7. PubMed ID: 1859363
[TBL] [Abstract][Full Text] [Related]
13. KRDS, a new peptide derived from human lactotransferrin, inhibits platelet aggregation and release reaction.
Mazoyer E; Lévy-Toledano S; Rendu F; Hermant L; Lu H; Fiat AM; Jollès P; Caen J
Eur J Biochem; 1990 Nov; 194(1):43-9. PubMed ID: 2174781
[TBL] [Abstract][Full Text] [Related]
14. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets.
Gartner TK; Bennett JS
J Biol Chem; 1985 Oct; 260(22):11891-4. PubMed ID: 2995350
[TBL] [Abstract][Full Text] [Related]
15. Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line.
Sheu JR; Lin CH; Chung JL; Teng CM; Huang TF
Thromb Res; 1992 Jun; 66(6):679-91. PubMed ID: 1519227
[TBL] [Abstract][Full Text] [Related]
16. Interaction of thrombin-activated platelets with extracellular matrices (fibronectin and vitronectin): comparison of the activity of Arg-Gly-Asp-containing venom peptides and monoclonal antibodies against glycoprotein IIb/IIIa complex.
Sheu JB; Ko WC; Hung WC; Peng HC; Huang TF
J Pharm Pharmacol; 1997 Jan; 49(1):78-84. PubMed ID: 9120775
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human platelet aggregation by GR91669, a prototype fibrinogen receptor antagonist.
Foster MR; Hornby EJ; Brown S; Hann M; Kitchin J; Pike N; Ward P
Thromb Res; 1994 Aug; 75(3):269-84. PubMed ID: 7992238
[TBL] [Abstract][Full Text] [Related]
18. Disagregin is a fibrinogen receptor antagonist lacking the Arg-Gly-Asp sequence from the tick, Ornithodoros moubata.
Karczewski J; Endris R; Connolly TM
J Biol Chem; 1994 Mar; 269(9):6702-8. PubMed ID: 8120028
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of extra- and intracellular calcium chelation on human platelet function and glycoprotein IIb-IIIa complex stability.
Lanza F; Stierlé A; Gachet C; Cazenave JP
Nouv Rev Fr Hematol (1978); 1992; 34(1):123-31. PubMed ID: 1523093
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets.
Ruggeri ZM; Houghten RA; Russell SR; Zimmerman TS
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5708-12. PubMed ID: 3016716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
